Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]

Chen Wei Chiang, Yun Shih Lin, Fu Ling Chang, Tsai Yu Lin, Keng Chang Tsai, Wei Chun HuangFu, Yu Ching Lee

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret aPh.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan bDepartment of Psychiatry, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan cPh.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan dNational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taipei, Taiwan ePh.D. Program in Medical Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan fTMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan>. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number149085
JournalBiochemical and Biophysical Research Communications
Volume686
DOIs
Publication statusPublished - Dec 17 2023

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Corrigendum to “Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer” [Biochem. Biophys. Res. Commun. 680 (2023) 161–170, (S0006291X23010616), (10.1016/j.bbrc.2023.09.025)]'. Together they form a unique fingerprint.

Cite this